A biotechnology company formed by two MPM Capital managing directors to develop monoclonal antibody drugs to fight cancer has been acquired by Novartis, according to a company statement. The move follows Novartis’ deal with University of Pennsylvania to collaborate on chimeric antigen receptor technology and reflects a relatively dramatic shift in the past year toward commercializing cancer immunotherapies.
CoStim Pharmaceuticals collaborated with Dana Farber Cancer Institute, Harvard Medical School, Boston Children’s Hospital, Brigham and Women’s Hospital and Immutep SA to develop a portfolio of agents focused on multiple T cell regulatory targets, the statement said.
The terms of the deal were not disclosed.
Where Will AI Deployment Benefit Payers the Most?
We are taking a look at how health insurers are using AI, defining success, and managing cybersecurity risks. Give us your opinions by completing our brief, anonymous survey.
Last year CoStim raised $10 million in a Series A round from MPM Capital and Atlas Ventures. Johnson & Johnson Development Corp. and Partners Innovation Fund also participated in the round.
Although using patients’ T cells to help them combat cancer is still very much in the early stages, researchers have been encouraged by its success in some blood cancers like acute myeloid leukemia. Other companies also see compelling opportunities in the space such as Kite Pharma,
In 2012, Novartis agreed to invest $20 million in a research and development center at Penn to commercialize novel cellular immunotherapies for cancer. Penn’s T cell research with Novartis is also the focus of a lawsuit by St Jude Children’s Research Hospital and, more recently, Juno Therapeutics.
Why Pharma Companies Should Look To Social Media For Better Patient Insight
Healthcare decision-makers, especially at pharmaceutical companies, must prioritize patient input. Data collected from social media listening is a significant step in the right direction.
Robert Millman was initially president of CoStim but Dr. Dan Hicklin later joined the company as chief scientific officer and president. Luke Evnin became the chairman.
[Photo credit: Credit: Peter Lane and Fiona McConnell, Wellcome Images]